Relationship of polymorphism of the tandem repeat sequence in the thymidylate synthase gene and the survival of stage III colorectal cancer patients receiving adjuvant 5‐flurouracil‐based chemotherapy
Authors:
- 18 December 2009
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 101 (1) , 22-27
Abstract
Background The aim of this study was to determine whether the different polymorphisms in the thymidylate synthase (TS) gene, novel G>C single nucleotide polymorphism (SNP) and variable number of tandem repeat (VNTR), may be related with disease-free survival (DFS) in patients with stage III colorectal cancer receiving adjuvant chemotherapy. Methods The study included 201 patients with pathologic TNM stage III colon cancer who received adjuvant 5-fluorouracil (5-FU)-based chemotherapy after surgery. DNA was extracted from fresh tumor tissue and sequenced. Patients with TS genotypes of 2R3G, 3C3G, or 3G3G were assigned to a high expression group, and those with 2R2R, 2R3C, or 3C3C, to a low expression group. Results Frequencies of the TS tandem repeat polymorphisms among the tumor genotypes were 6.0% in 2R2R, 25.4% in 2R3R, and 68.7% in 3R3R. The low expression group included 52 patients (25.9%), and the high expression group included 149 patients (74.1%). Groups classified according to possession of VNTR, SNP, and low- or high-expression genotypes did not differ significantly in DFS. In multivariate analysis, only tumor stage showed significant prognostic value (hazard ratio (HR) 2.05, 95% CI = 1.24–3.37, P = 0.005). Conclusions TS polymorphisms do not predict clinical outcome of colorectal cancer patients treated with adjuvant 5-FU-based chemotherapy. J. Surg. Oncol. 2010;101:22–27.Keywords
Funding Information
- Korean government (KRF-2007-313-E00004)
- IN-SUNG Foundation for Medical Research
This publication has 28 references indexed in Scilit:
- Tumor Thymidylate Synthase 1494del6 Genotype As a Prognostic Factor in Colorectal Cancer Patients Receiving Fluorouracil-Based Adjuvant TreatmentJournal of Clinical Oncology, 2006
- Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancersEuropean Journal of Cancer, 2005
- Thymidylate Synthase Gene Polymorphism as a Prognostic Factor for Colon CancerJournal of Gastrointestinal Surgery, 2005
- Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphism in Normal Tissue As Predictors of Fluorouracil SensitivityJournal of Clinical Oncology, 2005
- Single nucleotide polymorphism in the 5′ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil‐based chemotherapy in advanced colorectal cancer patientsInternational Journal of Cancer, 2004
- Thymidylate Synthase Expression and Prognosis in Colorectal Cancer: A Systematic Review and Meta-AnalysisJournal of Clinical Oncology, 2004
- Translational autoregulation of thymidylate synthase and dihydrofolate reductaseFrontiers in Bioscience-Landmark, 2004
- A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly PatientsNew England Journal of Medicine, 2001
- Ethnic Variation in the Thymidylate Synthase Enhancer Region Polymorphism among Caucasian and Asian PopulationsGenomics, 1999
- Functional Analysis and DNA Polymorphism of the Tandemly Repeated Sequences in the 5'-terminal Regulatory Region of the Human Gene for Thymidylate Synthase.Cell Structure and Function, 1995